Author:
Hardy W David,Gulick Roy M,Mayer Howard,Fätkenheuer Gerd,Nelson Mark,Heera Jayvant,Rajicic Natasa,Goodrich James
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Pharmacology (medical),Infectious Diseases
Reference18 articles.
1. Maraviroc (UK-427,857): a potent, orally bioavailable and selective small-molecule inhibitor of the chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.;Dorr;Antimicrob Agents Chemother,2005
2. for the MOTIVATE Study Teams. Maraviroc for previously treated patients with R5 HIV-1 infection.;Gulick;N Engl J Med,2008
3. for the MOTIVATE 1 and MOTIVATE 2 Study Teams. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.;Fatkenheuer;N Engl J Med,2008
4. Hepatotoxicity observed in clinical trials of aplaviroc (GW873140).;Nichols;Antimicrob Agents Chemother,2008
5. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS clinical trials group 5211.;Gulick;J Infect Dis,2007
Cited by
74 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献